Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
May 04, 2022 08:01 ET
|
Phathom Pharmaceuticals
Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE)Provides capital for launch of vonoprazan in H. pylori...
Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population
April 26, 2022 08:19 ET
|
Biomerica, Inc.
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
March 01, 2022 16:04 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021
January 13, 2022 08:19 ET
|
Biomerica, Inc.
Revenues up 239% over prior year fiscal second quarter Customer orders backlog of over $4.0 million at November 30, 2021 Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon...
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
November 08, 2021 08:00 ET
|
Phathom Pharmaceuticals
Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were accepted for filing by FDA with six-month Priority Review granted; PDUFA target action date of May...
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
October 24, 2021 15:30 ET
|
Phathom Pharmaceuticals
Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical ResearchPhase 1 population PK data abstract concludes the...
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
October 21, 2021 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
September 20, 2021 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
August 31, 2021 07:45 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
August 02, 2021 08:30 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...